SCHEMBL560937

SCHEMBL560937

COC(=O)c1cnc(N)c(-c2nc3ccc(C)cc3[nH]2)n1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ATR Q13535 11/20 0.55
KDM4E B2RXH2 4/20 0.48
ALDH1A1 P00352 4/20 0.48
MAPT P10636 3/20 0.48
HPGD P15428 3/20 0.48
POLB P06746 1/20 0.48
HPSE Q9Y251 1/20 0.46
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
GAA P10253 1/20 0.44
TP53 P04637 1/20 0.44
PKM P14618 1/20 0.44
GFER P55789 1/20 0.44
FLT3 P36888 1/20 0.43
ALOX5 P09917 1/20 0.43
EPHX2 P34913 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL559840 0.85 ATR (0.51) ATRKDM4EALDH1A1MAPTHPGD
SCHEMBL560594 0.85 ATR (0.55) ATRKDM4EALDH1A1MAPTHPGD
SCHEMBL560593 0.82 MMP2 (0.58) ATRKDM4EALDH1A1MAPTHPGD
SCHEMBL10166538 0.82 ATR (0.57) ATRKDM4EALDH1A1MAPTHPGD
SCHEMBL560220 0.82 ATR (0.53) ATRKDM4EALDH1A1MAPTHPGD
SCHEMBL559824 0.82 ATR (0.54) ATRFLT3
SCHEMBL560627 0.82 ATR (0.52) ATRKDM4EALDH1A1MAPTHPGD
SCHEMBL560124 0.81 ATR (0.52) ATRKDM4EALDH1A1MAPTHPGD
SCHEMBL560074 0.81 ATR (0.52) ATRKDM4EALDH1A1MAPTHPGD
SCHEMBL561267 0.81 CYP1A2 (0.49) ATRALDH1A1HPGDPOLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
WO-2011143419-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 ATR 1/4885KDM4E 2074/4885ALDH1A1 4062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.